Medtide (FQ2) Stock Overview
A contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FQ2 from our risk checks.
FQ2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Medtide Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.52 |
| 52 Week High | HK$4.47 |
| 52 Week Low | HK$2.08 |
| Beta | 0 |
| 1 Month Change | 0.80% |
| 3 Month Change | 11.50% |
| 1 Year Change | -27.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| FQ2 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -8.4% | 0.1% |
| 1Y | -27.9% | 0.1% | -0.5% |
Return vs Industry: FQ2 underperformed the German Life Sciences industry which returned 0.1% over the past year.
Return vs Market: FQ2 underperformed the German Market which returned -0.5% over the past year.
Price Volatility
| FQ2 volatility | |
|---|---|
| FQ2 Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: FQ2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FQ2's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 566 | Vickie Xu | www.medtideinc.com |
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products.
Medtide Inc. Fundamentals Summary
| FQ2 fundamental statistics | |
|---|---|
| Market cap | €375.75m |
| Earnings (TTM) | €28.22m |
| Revenue (TTM) | €74.01m |
Is FQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FQ2 income statement (TTM) | |
|---|---|
| Revenue | CN¥570.09m |
| Cost of Revenue | CN¥208.48m |
| Gross Profit | CN¥361.61m |
| Other Expenses | CN¥144.24m |
| Earnings | CN¥217.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.53 |
| Gross Margin | 63.43% |
| Net Profit Margin | 38.13% |
| Debt/Equity Ratio | 1.9% |
How did FQ2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 23:44 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medtide Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurence Tam | Morgan Stanley |